DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 172 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $4,914,461 | -25.3% | 312,426 | -23.4% | 0.01% | -20.0% |
| Q4 2023 | $6,579,943 | +1641.4% | 407,932 | +1273.2% | 0.02% | +1400.0% |
| Q3 2023 | $377,860 | -73.1% | 29,706 | -70.2% | 0.00% | -75.0% |
| Q2 2023 | $1,403,860 | -49.2% | 99,706 | -44.2% | 0.00% | -50.0% |
| Q1 2023 | $2,761,008 | -53.0% | 178,706 | -50.2% | 0.01% | -55.6% |
| Q4 2022 | $5,876,684 | +2.9% | 358,553 | +16.1% | 0.02% | -5.3% |
| Q3 2022 | $5,711,000 | +176.6% | 308,700 | +96.5% | 0.02% | +171.4% |
| Q2 2022 | $2,065,000 | +38.5% | 157,069 | +2.9% | 0.01% | +133.3% |
| Q4 2021 | $1,491,000 | -74.5% | 152,649 | +56.0% | 0.00% | -89.7% |
| Q2 2020 | $5,844,000 | +19.6% | 97,854 | -17.5% | 0.03% | -27.5% |
| Q1 2020 | $4,885,000 | +57.3% | 118,655 | +137.8% | 0.04% | +344.4% |
| Q4 2019 | $3,105,000 | +123.1% | 49,895 | +21.6% | 0.01% | +80.0% |
| Q3 2019 | $1,392,000 | +197.4% | 41,021 | +244.7% | 0.01% | +400.0% |
| Q2 2018 | $468,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $19,824,869 | 14.35% |
| Redmile Group, LLC | 3,593,317 | $58,894,466 | 2.41% |
| BRAIDWELL LP | 3,271,513 | $53,620,098 | 1.80% |
| Parkman Healthcare Partners LLC | 344,920 | $5,653,239 | 1.50% |
| ARMISTICE CAPITAL, LLC | 5,172,000 | $84,769,080 | 1.48% |
| Ikarian Capital, LLC | 367,119 | $6,017,081 | 1.45% |
| Sunesis Advisors, LLC | 96,299 | $1,578,341 | 1.01% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,349,228 | $38,503,847 | 0.80% |
| Hillsdale Investment Management Inc. | 328,200 | $5,379,198 | 0.46% |
| Avidity Partners Management LP | 1,126,000 | $18,455,140 | 0.40% |